Pharmacological Development of Treatment Agents and Formulations for Tobacco Dependence (STTR [R41]

The summary for the Pharmacological Development of Treatment Agents and Formulations for Tobacco Dependence (STTR [R41] grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Pharmacological Development of Treatment Agents and Formulations for Tobacco Dependence (STTR [R41]: Purpose. The goal of this Funding Opportunity Announcement (FOA) issued by the National Institute on Drug Abuse (NIDA) is to facilitate the development of new, more effective treatments for tobacco dependence. Mechanism of Support. This FOA will utilize the STTR (R41) grant mechanisms for Phase I applications. Funds Available and Anticipated Number of Awards. The estimated amount of funds available for support of 4-7 projects awarded as a result of this announcement is $1,500,000 for fiscal year 2011. Future year amounts will depend on annual appropriations. Budget and Project Period. For these Phase I projects, budgets up to $300,000 total costs for a time period of up to one year may be requested.